Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral Diammonium Glycyrrhizinate for Attenuating Toxicity and Enhancing Efficacy of CAR-T Cell Therapy
NCT07616271Phase 3Not yet recruiting
- Sponsor
- Tongji Hospital
- Start
- May 2026
- Primary completion
- May 2029
01
Overview
A Phase 3 trial of glycyrrhizin in diffuse large B-cell lymphoma (DLBCL), cytokine release syndrome (CRS), sponsored by Tongji Hospital. Planned start May 2026; status: not yet recruiting.
02
Drugs
glycyrrhizin
03
Conditions
diffuse large B-cell lymphoma (DLBCL)cytokine release syndrome (CRS)
Beyond the preview
Go deeper on NCT07616271.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07616271.